866-997-4948(US-Canada Toll Free)

Pemphigus Vulgaris - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 54 Pages

Pemphigus Vulgaris - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2017, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pemphigus Vulgaris - Overview 6
Pemphigus Vulgaris - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Pemphigus Vulgaris - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Pemphigus Vulgaris - Companies Involved in Therapeutics Development 20
arGEN-X BV 20
Biogen Inc 20
HanAll Biopharma Co Ltd 21
Immunomedics Inc 21
Novartis AG 21
Principia Biopharma Inc 22
Pemphigus Vulgaris - Drug Profiles 23
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DPC-006 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
efgartigimod alfa - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HL-161 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PRN-1008 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
rituximab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
SYNT-001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
VAY-736 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
veltuzumab - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Pemphigus Vulgaris - Dormant Projects 46
Pemphigus Vulgaris - Discontinued Products 47
Pemphigus Vulgaris - Product Development Milestones 48
Featured News & Press Releases 48
Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-113 48
Sep 26, 2017: argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris 48
Sep 18, 2017: Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting 49
Jul 11, 2017: Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris 49
Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris 50
Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 51
Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development for Pemphigus Vulgaris, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pemphigus Vulgaris - Pipeline by arGEN-X BV, H2 2017 20
Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2017 20
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H2 2017 21
Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H2 2017 21
Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2017 22
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H2 2017 22
Pemphigus Vulgaris - Dormant Projects, H2 2017 46
Pemphigus Vulgaris - Discontinued Products, H2 2017 47

List of Figures
Number of Products under Development for Pemphigus Vulgaris, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *